Raymond James Financial
GPCR icon

Raymond James Financial’s Structure Therapeutics GPCR Stock Holding History

Raymond James Financial’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.19M Buy
59,357
+14,218
+31% +$629K ﹤0.01% 3120
2026
Q1 		$2.18M Buy
45,139
+751
+2% +$51.4K ﹤0.01% 3298
2025
Q4 		$3.09M Buy
+44,388
New +$1.81M ﹤0.01% 2911
2025
Q3 		– Sell
-6,229
Closed -$129K – 5687
2025
Q2 		$129K Buy
+6,229
New +$137K ﹤0.01% 4734

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Raymond James Financial's GPCR Position: Q2 2026 in Review

Raymond James Financial increased its Structure Therapeutics (GPCR) stake by 31% in Q2 2026, buying an estimated $629K and bringing the position to 59,357 shares worth $3.19M. The position accounts for ﹤0.01% of the portfolio, ranked #3120.

Raymond James Financial first reported a position in GPCR in Q2 2025 and has held it in 4 quarters since. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Raymond James Financial held 59,357 shares of Structure Therapeutics worth $3.19M as of Q2 2026.
  • Raymond James Financial bought 14,218 Structure Therapeutics shares in Q2 2026, an estimated $629K.
  • Structure Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3120 holding.
  • Raymond James Financial first reported a position in Structure Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.